SMDM Conference

ISPOR's 19th Annual European meeting starts on Sunday, 10/29 in Vienna, Austria.  Here is a list of presentations and discussions by our CEVR investigators:


Poster Presentation
Do first-in-class drugs offer larger incremental health gains than next-in-class drugs?
Monday, 10/31 3:45-5:45pm
James Chambers, PhD, MPharm


Issue Panel

Emerging US Value Frameworks: Are there lessons from -or for- Europe?
Tuesday, 11/1 1:45-2:45pm
Peter Neumann, ScD

2nd Panel on Cost-Effectiveness for Health and Medicine

The 2nd Panel on Cost-Effectiveness for Health and Medicine will host a one-day conference highlighting their findings and recommendations. The conference will be held December 7th in Washington, DC. Click Here for registration information.

The agenda for the 2nd Panel on Cost-Effectiveness in Health and Medicine's conference is available



Interview with interviewed Paige Lin, PhD to discuss her recent paper, "Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Prior to and Following Diagnosis", published online in JAGS. To read the full interview, click here.

CEA Registry Update

CEA Registry update: The database now contains 5,000 studies and over 13,000 standardized cost-effectiveness ratios.


Growth and change in the CUA literature CEVR researchers published a new paper in Value in Health: “The Changing Face of the Cost-Utility Literature."


New paper by CEVR researchers in Value in Health: “Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence."


New paper by CEVR researchers in the American Journal of Managed Care: “Multiple Chronic Conditions in Type 2 Diabetes Mellitus: Prevalence and Consequences."


Special report from CEVR researchers in Expert Review of Pharmacoeconomics and Outcomes Research: "The lag from FDA approval to published cost-utility evidence."


New paper by CEVR researchers in the journal Blood: “Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.”